Traditional Chinese medicine is expected to be used in Meicheng prescription

On November 3, our reporter learned from the 64th Annual Meeting of American Society of hepatology in Washington that "Fuzheng Huayu tablet", a compound Chinese herbal medicine against liver fibrosis, has successfully completed the second phase clinical trial of the US Food and Drug Administration (FDA) This marks the first time that Chinese anti fibrosis compound Chinese medicine is expected to enter the mainstream pharmaceutical market in the United States At a satellite meeting held on the same day, Professor Hassani, the main researcher of the above clinical trial and director of the clinical research center for liver diseases of Southern California State University, announced that after three years of research, Fuzheng Huayu tablet has clinical efficacy in improving liver fibrosis of chronic hepatitis C, with high safety and good tolerance Professor Liu Ping, one of the main developers of the drug and vice president of Shanghai University of traditional Chinese medicine, told our reporter that anti liver fibrosis has always been a blank field in western medicine, and no effective drugs have been developed so far In recent 10 years, the clinical treatment experience of Fuzheng Huayu tablet has found that traditional Chinese medicine has its unique efficacy in the treatment of liver cirrhosis, so promoting the successful completion of the second phase clinical trial of FDA in the United States is a major breakthrough, which can be said to fill the gap in the Western medical community "The FDA, known for its strict supervision, has been skeptical of Chinese herbal products for many years Only through scientific experiments and facts can we dispel Western doubts " Liu Ping said As the first compound Chinese medicine developed by Shanghai Modern Chinese Medicine Co., Ltd., Fuzheng Huayu tablet is the first Chinese medicine to select patients who have failed in western medicine treatment and are difficult to treat for clinical research abroad Bian fossil, general manager of the company, told our reporter that Fuzheng Huayu tablet has been listed and sold in China for about 800000 patients, and the annual sales volume is about to exceed 250 million yuan In 2010, after the approval of FDA, the drug was exempted from the first phase of clinical trials and directly entered the second phase of clinical trials, and 100 local patients in the United States participated in the study "Chinese and Western medicine are two distinct medical systems," he said "If traditional Chinese medicine is to go abroad and be recognized, it is necessary to come up with a set of persuasive and excellent data for others to recognize you." It is reported that after the completion of the second phase clinical trial, Fuzheng Huayu tablet will wait for the approval of the US FDA, and start a more stringent third phase clinical trial as soon as possible It is expected to be sold in the United States as a prescription drug within four to five years Founded in 1950, the American Society for the study of liver diseases is the most important international academic organization in the field of liver disease research At present, it has more than 2700 expert members and researchers from around the world From November 1 to 5, the 64th Annual Meeting of the American Society of Hepatology was held in Washington Conference Center Shanghai Modern Chinese Medicine Co., Ltd is the first Chinese exhibitor invited to attend the annual meeting.